J
Jerome Ritz
Researcher at Harvard University
Publications - 681
Citations - 52921
Jerome Ritz is an academic researcher from Harvard University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 120, co-authored 644 publications receiving 47987 citations. Previous affiliations of Jerome Ritz include University of Minnesota & Tehran University of Medical Sciences.
Papers
More filters
Journal ArticleDOI
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
TL;DR: The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.
Journal ArticleDOI
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth,Ken-ichi Matsuoka,Haesook T. Kim,Sean McDonough,Bhavjot Bindra,Edwin P. Alyea,Philippe Armand,Corey Cutler,Vincent T. Ho,Nathaniel S. Treister,Don C. Bienfang,Sashank Prasad,Dmitrios Tzachanis,Robin Joyce,David Avigan,Joseph H. Antin,Jerome Ritz,Robert J. Soiffer +17 more
TL;DR: Daily low-dose interleukin-2 was safely administered in patients with active chronic GVHD that was refractory to glucocorticoid therapy and was associated with preferential, sustained Treg cell expansion in vivo and amelioration of the manifestations of chronic GvHD in a substantial proportion of patients.
Journal ArticleDOI
Biology and clinical relevance of human natural killer cells.
Michael J. Robertson,Jerome Ritz +1 more
TL;DR: Information about subscriptions and ASH membership may be found online at: reserved.org.
Journal ArticleDOI
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin,Annabelle J. Anandappa,Jing Sun,Itay Tirosh,Nathan Mathewson,Shuqiang Li,Giacomo Oliveira,Anita Giobbie-Hurder,Kristen Felt,Evisa Gjini,Sachet A. Shukla,Zhuting Hu,Letitia Li,Phuong M. Le,Rosa Lundbye Allesøe,Rosa Lundbye Allesøe,Alyssa R. Richman,Monika S. Kowalczyk,Sara Abdelrahman,Jack Geduldig,Sarah Charbonneau,Kristine Pelton,J. Bryan Iorgulescu,Liudmila Elagina,Wandi Zhang,Oriol Olive,Christine McCluskey,Lars Rønn Olsen,Jonathan Stevens,William J. Lane,Andres M. Salazar,Heather Daley,Patrick Y. Wen,E. Antonio Chiocca,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Gad Getz,Eric S. Lander,Aviv Regev,Jerome Ritz,Donna Neuberg,Scott J. Rodig,Keith L. Ligon,Mario L. Suvà,Kai W. Wucherpfennig,Nir Hacohen,Edward F. Fritsch,Kenneth J. Livak,Patrick A. Ott,Catherine J. Wu,David A. Reardon +51 more
TL;DR: It is demonstrated that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load and an immunologically ‘cold’ tumour microenvironment.
Journal ArticleDOI
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
Lawrence S. Young,C Alfieri,Kevin Hennessy,H Evans,C O'Hara,KC Anderson,Jerome Ritz,R S Shapiro,Alan B. Rickinson,Elliott Kieff +9 more
TL;DR: Using monoclonal antibody-immune microscopy, it is demonstrated that these two EBV proteins and their associated B-lymphocyte activation or adhesion molecules are expressed in the infiltrating B lymphocytes in immunocompromised patients with EBV lymphoproliferative disease.